SAN FRANCISCO, Jan. 13 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Canada) a clinical-stage biotherapeutics company, is pleased to announce that Samantha Miller has been appointed to the position of Vice President of Corporate Development.
Ms. Miller has over 15 years of biotechnology and pharmaceutical business development experience, and has negotiated, executed and managed numerous global partnerships, as well as regional partnerships in the United States, Europe, Japan and elsewhere. She has been involved in executing over 30 partnerships and licenses, with companies such as GlaxoSmithKline, Eli Lilly, Johnson & Johnson, AstraZeneca, Astellas and others.
Ms. Miller has held senior positions in business development, including the title of Vice President, in various companies including Anesiva, Theravance, Scios Pharmaceuticals, Onyx Pharmaceuticals and Procter & Gamble Pharmaceuticals.
"Samantha is an outstanding addition to our executive management team. As Jennerex continues to report compelling Phase 1 and 2 clinical data from its oncology programs, Samantha joins us at an opportune time for the development of additional strategic partnerships," said David H. Kirn, M.D., President and Chief Executive Officer. "We have clear regulatory pathways to large global cancer markets with multiple products, and Samantha's addition to the Jennerex team further endorses the potential of the Company's product platform," added Dr. Kirn.
Ms. Miller holds a BS in Biochemistry/ Cell Biology from UCSD, and she
holds Masters degrees in both Immunology and in Business Administration (MBA)
Jennerex is a clinical-stage biotherapeutics company focused on the
development and commercialization of first-in-class, breakthrough targeted
oncolytic products for cancer. The company's lead
|SOURCE Jennerex, Inc.|
Copyright©2009 PR Newswire.
All rights reserved